File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention

TitleCelecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention
Authors
Issue Date2008
PublisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm
Citation
World Journal Of Gastroenterology, 2008, v. 14 n. 28, p. 4535-4539 How to Cite?
AbstractAim: To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study. Methods: From 2004 to 2006, a total of 1024 Chinese patients (aged 35 to 64 years) with severe chronic atrophic gastritis, intestinal metaplasia or dysplasia were randomly assigned to receive 200 mg of celecoxib twice daily or placebo in Linqu County (Shandong Province, China), a high-risk area of gastric cancer. All gastroduodenal ulcer and cardiovascular events occurred were recorded and the patients were followed up for 1.5 years after treatment. At the end of the trial, a systematic interview survey about other adverse events was conducted. Results: Gastroduodenal ulcer was detected in 19 of 463 (3.72%) patients who received celecoxib and 17 of 473 (3.31%) patients who received placebo, respectively (odds ratio = 1.13, 95% CI = 0.58-2.19). Cardiovascular (CV) events occurred in 4 patients who received celecoxib and in 5 patients who received placebo, respectively. Compared with those who received placebo, patients who received celecoxib had no significant increase in occurrence of CV events (hazard ratio = 0.84, 95% CI = 0.23-3.15). Among the adverse events acquired by interview survey, only the frequency of bloating was significantly higher in patients treated with celecoxib than in those treated with placebo. Conclusion: Treatment of gastric cancer with celecoxib is not associated with increased risk of gastroduodenal ulcer and cardiovascular events. © 2008 The WJG Press. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/59359
ISSN
2015 Impact Factor: 2.787
2015 SCImago Journal Rankings: 1.076
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFeng, GSen_HK
dc.contributor.authorMa, JLen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorZhang, Len_HK
dc.contributor.authorLiu, WDen_HK
dc.contributor.authorPan, KFen_HK
dc.contributor.authorShen, Len_HK
dc.contributor.authorZhang, XDen_HK
dc.contributor.authorLi, Jen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorLi, JYen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorYou, WCen_HK
dc.date.accessioned2010-05-31T03:48:24Z-
dc.date.available2010-05-31T03:48:24Z-
dc.date.issued2008en_HK
dc.identifier.citationWorld Journal Of Gastroenterology, 2008, v. 14 n. 28, p. 4535-4539en_HK
dc.identifier.issn1007-9327en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59359-
dc.description.abstractAim: To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study. Methods: From 2004 to 2006, a total of 1024 Chinese patients (aged 35 to 64 years) with severe chronic atrophic gastritis, intestinal metaplasia or dysplasia were randomly assigned to receive 200 mg of celecoxib twice daily or placebo in Linqu County (Shandong Province, China), a high-risk area of gastric cancer. All gastroduodenal ulcer and cardiovascular events occurred were recorded and the patients were followed up for 1.5 years after treatment. At the end of the trial, a systematic interview survey about other adverse events was conducted. Results: Gastroduodenal ulcer was detected in 19 of 463 (3.72%) patients who received celecoxib and 17 of 473 (3.31%) patients who received placebo, respectively (odds ratio = 1.13, 95% CI = 0.58-2.19). Cardiovascular (CV) events occurred in 4 patients who received celecoxib and in 5 patients who received placebo, respectively. Compared with those who received placebo, patients who received celecoxib had no significant increase in occurrence of CV events (hazard ratio = 0.84, 95% CI = 0.23-3.15). Among the adverse events acquired by interview survey, only the frequency of bloating was significantly higher in patients treated with celecoxib than in those treated with placebo. Conclusion: Treatment of gastric cancer with celecoxib is not associated with increased risk of gastroduodenal ulcer and cardiovascular events. © 2008 The WJG Press. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htmen_HK
dc.relation.ispartofWorld Journal of Gastroenterologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAdulten_HK
dc.subject.meshCardiovascular Diseases - chemically induceden_HK
dc.subject.meshChinaen_HK
dc.subject.meshCyclooxygenase 2 Inhibitors - adverse effects - therapeutic useen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshIncidenceen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMyocardial Infarction - chemically induceden_HK
dc.subject.meshPeptic Ulcer - chemically induceden_HK
dc.subject.meshPyrazoles - adverse effects - therapeutic useen_HK
dc.subject.meshRisk Factorsen_HK
dc.subject.meshStomach Neoplasms - prevention & controlen_HK
dc.subject.meshStroke - chemically induceden_HK
dc.subject.meshSulfonamides - adverse effects - therapeutic useen_HK
dc.titleCelecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer preventionen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3748/wjg.14.4535en_HK
dc.identifier.pmid18680235-
dc.identifier.pmcidPMC2731282-
dc.identifier.scopuseid_2-s2.0-58049089743en_HK
dc.identifier.hkuros158963en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58049089743&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue28en_HK
dc.identifier.spage4535en_HK
dc.identifier.epage4539en_HK
dc.identifier.isiWOS:000258263500017-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridFeng, GS=15065477300en_HK
dc.identifier.scopusauthoridMa, JL=36077415400en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridZhang, L=9941148200en_HK
dc.identifier.scopusauthoridLiu, WD=7407342511en_HK
dc.identifier.scopusauthoridPan, KF=7102713586en_HK
dc.identifier.scopusauthoridShen, L=7401703978en_HK
dc.identifier.scopusauthoridZhang, XD=36071948600en_HK
dc.identifier.scopusauthoridLi, J=36063614900en_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridLi, JY=8691647000en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridYou, WC=18041451900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats